Taking Charge—biotechs already approaching Novartis to partner on 'game changing' CAR-T platform Long COVID, brief dream: Phase 2 flop sparks end of PureTech's bid to treat coronavirus complications BridgeBio bounces back? Phase 2 readout provides hope for approval of drug to rebalance calcium levels Sponsored: An Integrated Approach to Developing Next-Generation Genomic Medicines After backdoor attempt, Stealth will try old-fashioned FDA business meeting to save elamipretide J&J jumps onto Evotec’s receptor platform in drug discovery deal Biotech edges toward gender parity, but C-suites stay male, white With $1B already in for Dren Bio, Pfizer adds to pile in $65M financing Has Denali found a way to correct gene mutations linked to Parkinson's? Possibly, but questions remain The top 10 most profitable pharma companies in 2021 Into the thick of it: Scientists discover mechanism behind certain heart disorders Rune Labs translates Apple Watch data into Parkinson's insights with FDA nod Alnylam's next-gen RNA drug Amvuttra wins FDA approval—and a Pfizer showdown may await Health IT execs skeptical of Oracle's lofty vision to build national medical records system Stopping cells from exchanging DNA 'packets' could halt bacterial resistance, study shows Featured Story | By James Waldron With the first generation of CAR-T therapies having shaken up the cancer space, all eyes are on what comes next. So it shouldn’t be a surprise that biotechs have already been in touch with Novartis to see whether they can jump onto the Swiss pharma’s T-Charge platform. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor PureTech Health’s long COVID trial has come up short. The drug candidate failed to help patients with the condition walk farther, prompting the company to drop plans for further studies in the indication. read more By Gabrielle Masson After a series of unfortunate events for BridgeBio Pharma, the biotech may be on a new upward trajectory as it unveiled positive data from 13 patients taking a drug to treat low calcium levels. read more Sponsored by: Danaher Corporation The life sciences companies at Danaher enable gene editing, gene therapy and mRNA medicines with integrated solutions that improve research, development and manufacturing. read more By Annalee Armstrong After attempting to sneak in the back door and getting it slammed in its face, Stealth BioTherapeutics has been given a chance at a good old-fashioned business meeting to shore up an FDA application for a Barth syndrome drug. read more By James Waldron Johnson & Johnson has signed up to use Evotec’s TargetAlloMod platform to discover what it hopes will be first-in-class therapies based on high potential cell surface targets. read more By Nick Paul Taylor Biotech’s slow shuffle toward increased representation of women and employees of color continued in 2021, with BIO’s third annual survey revealing progress but also the need for further improvements. read more By Gabrielle Masson Dren Bio—a biotech developing therapeutic antibodies for patients with cancer and autoimmune diseases—has closed a $65 million series B financing round, with new investor Big Pharma Pfizer jumping on board following a recent oncology partnership with the biotech. read more By Max Bayer Denali is touting an initial tranche of data as evidence that targeting genetic mutations linked to Parkinson's holds therapeutic promise. read more By Angus Liu,Eric Sagonowsky,Kevin Dunleavy,Fraiser Kansteiner,Zoey Becker While revenue reflects how well a pharma company’s products and services are selling, profit represents another important measurement that provides investors a look at the health of the business and how efficiently it has been managed. Here, we rank the top 10 pharma companies by 2021 net income. read more By Gabrielle Masson Scientists have uncovered a mechanism behind the thickening of the heart muscle wall—a process tied to higher risk of irregular heart rhythms and heart failure. read more By Andrea Park With the importance of accurate self-reporting for Parkinson's treatment, a spate of apps and other digital tools have cropped up to help patients keep track of their symptoms. One such tool newly cleared by the FDA takes the concept a step further, bringing in the Apple Watch’s movement-analysis abilities to take on some of the tracking itself. read more By Angus Liu Alnylam’s closely watched Onpattro follow-on therapy, vutrisiran, has snagged a much-anticipated FDA green light. The approval tees up a possible showdown with Pfizer’s blockbuster Vyndaqel franchise in an increasingly competitive rare disease field. read more By Heather Landi Oracle chairman Larry Ellison's vision to use the power of Cerner to build a national health records database is a lofty ambition, health IT professionals say, but it's an aspiration that will take an unprecedented level of industry collaboration to execute. read more By James Waldron Bacterial resistance is one of the biggest looming health threats for modern medicine, but new research by a transatlantic team of researchers has offered a better understanding of how this resistance spreads—and how to stop it. read more Resources Sponsored by: PwC Don’t miss these critical considerations when evaluating your HCP interactions management program. Sponsored By: Thermo Fisher Scientific Sponsored by Thermo Fisher Scientific The journey for starting or expanding a lab can be exhilarating, while also being challenging--learn how this free program provides savings and solutions to support your goals. Sponsored By: CG Life Explore the new cell therapy handbook from Thermo Fisher Scientific. Sponsored by: Merit Solutions Quality operations guide your organization through regulatory compliance processes and safeguard your products, processes, and reputation. But your team is capable of so much more. Quality incident data and processes can be a driver of significant business value if shared with other stakeholders. Sponsored by: Blue Matter, strategic consultants in the life sciences Recent trends are driving big changes in Medical Affairs. This paper explores why, and what MA teams can do to stay ahead of the curve. Sponsored by: Catalent Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Fierce Digital Pharma Engage June 14-15, 2022 | Huntington Beach, CA Fierce Digital Pharma Innovation Week June 21-23, 2022 | Virtual Event Fierce Biotech Summit September 19-20, 2022 | Boston, MA Fierce New Product Planning Summit September 20-22, 2022 | Boston, MA Fierce Digital Pharma East October 18-20, 2022 | Philadelphia, PA & October 25-28, 2022 | Virtual Event Fierce Pharma Meeting Professionals Summit November 2-3, 2022 | Atlantic City, NJ Fierce European Trial Master File Summit November 14-16, 2022 | London, UK Fierce Launch Readiness for Medical Affairs & Communications Teams Summit November 30-December 1, 2022 | Virtual Event Fierce JPM Week 2023 January 2023 | San Francisco, CA & Virtual | 